Aventis Pharma: Strategy paying off - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aventis Pharma: Strategy paying off

Oct 21, 2003

Aventis Pharma announced its 3QFY04 results last week. While the company has reported a marginal 2% growth in the topline, operating efficiencies have helped it record a sharp 57% rise in bottomline. For 9mFY04 also, the company has reported a 6% and 54% growth in net sales and net profit respectively. In this context, let us take a brief look at the company’s performance.

Results at a glance…
(Rs m)3QFY033QFY04Change9mFY039mFY04Change
Net Sales1,5921,6282.3%4,5734,8285.6%
Other Income316196.8%7312976.7%
Expenditure1,3281,264-4.8%3,8673,8910.6%
Operating Profit (EBDIT)26436437.9%70693732.7%
Operating Profit Margin (%)16.6%22.4% 15.4%19.4% 
Interest 10 40 
Depreciation38380.0%1131184.4%
Profit before Tax25638751.2%66294843.2%
Extraordinary income-5-5 -455 
Tax8512142.4%21532048.8%
Profit after Tax/(Loss)16626157.2%44368354.2%
Net profit margin (%)10.4%16.0% 9.7%14.1% 
No. of Shares (m)2323 2323 
Earnings per share (Rs)*28.945.4 25.739.6 
P/E (x) 11.2  12.8 

Aventis Pharma’s aggressive marketing strategy has helped it record a 7% growth in domestic sales during 3QFY03. The growth was fuelled by the good performance recorded by its strategic brands. Cardace (40%), Targocid (29%), Amarly (23%) and Clexane (17%) recorded impressive growth during the quarter. Among other major products, Combiflam (18% growth), Avil (10%) and Soframycin (9%) also continued to maintain leadership position in their respective segments. However, a 26% drop in export revenues stunted this growth. This was primarily on account of a drop in the overseas demand. Also, last year’s September quarter was exceptionally good for exports (34% growth over 3QFY02).

Cost break-up
(Rs m)3QFY033QFY04% Change9mFY039mFY04% Change
Raw material 886830-6%2,4252,4431%
Staff cost11913312%3834076%
Others323301-7% 1,059 1,041-2%
Total Expenditure 1,328 1,264 -5%3,8673,8911%

Despite flat growth in the topline, Aventis Pharma managed to improve its operating efficiency resulting in a 5.8 percentage points improvement in operating margins. This was primarily on account of a drop in the raw material cost as a percentage of sales from 56% in 3QFY03 to 51% in 3QFY04. Other income increased due to higher interest and dividend income. Thus, higher operating margins and a sharp increase in the net margins have helped the company record a 57% rise in net profits.

Continuing with its strategy of aggressive new product launches from its parent’s product portfolio, Aventis Pharma launched ‘Lantus’, world’s only 24-hour basal insulin in the anti – diabetics segment. Although, the company has separately disclosed Lantus’s performance in the current period, we expect it to be a top performer given its global success. ‘Lantus’ is likely to be one of the major growth drivers for the company going forward.

At Rs 506, Aventis Pharma is trading at a P/E of 13x its 9mFY04 earnings. Given the company's aggressive new product launches and the resultant new product portfolio, declining DPCO cover and focus on lifestyle segments, we remain positive about the long-term prospects of the company. However, although Aventis Pharma has been successfully charging a premium for its products, the sustainability of the same in view of the rising competition in the domestic market remains a concern as this could put pressure on its margins. For more on Aventis, view the Research Report

Equitymaster requests your view! Post a comment on "Aventis Pharma: Strategy paying off". Click here!

  

More Views on News

SANOFI INDIA 2019-20 Annual Report Analysis (Annual Result Update)

Oct 25, 2021 | Updated on Oct 25, 2021

Here's an analysis of the annual report of SANOFI INDIA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

How to Hit Rs 100 Crore Wealth in Your Lifetime (Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Nov 26, 2021 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ACTAVIS COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS